Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VNRX 
Volitionrx Ltd (VNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VNRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.94
1 Year Target Price $2.94
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.02% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 73.57M USD | Price to earnings Ratio - | 1Y Target Price 2.94 |
Price to earnings Ratio - | 1Y Target Price 2.94 | ||
Volume (30-day avg) 6 | Beta 1.26 | 52 Weeks Range 0.40 - 0.94 | Updated Date 08/15/2025 |
52 Weeks Range 0.40 - 0.94 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.0467 | Actual -0.0653 |
Profitability
Profit Margin - | Operating Margin (TTM) -2241.09% |
Management Effectiveness
Return on Assets (TTM) -108.04% | Return on Equity (TTM) -730.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82259553 | Price to Sales(TTM) 56.23 |
Enterprise Value 82259553 | Price to Sales(TTM) 56.23 | ||
Enterprise Value to Revenue 62.35 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 105873000 | Shares Floating 71538947 |
Shares Outstanding 105873000 | Shares Floating 71538947 | ||
Percent Insiders 18.61 | Percent Institutions 23.38 |
Upturn AI SWOT
Volitionrx Ltd
Company Overview
History and Background
VolitionRx Limited (VNRX) is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Founded to focus on NuQu00ae Nucleosomics technology, which can identify and measure nucleosomes, which are fundamental components of chromatin, the structure that organizes DNA in cells. They were established in 2010.
Core Business Areas
- Cancer Diagnostics: Development and commercialization of blood-based cancer diagnostic tests using their NuQu00ae platform to detect and diagnose various cancers at early stages.
- Research and Development: Ongoing research and development efforts focused on expanding the application of their NuQu00ae technology to other diseases and improving the accuracy and efficiency of their diagnostic tests.
Leadership and Structure
Cameron Reynolds is the current CEO. The company has a board of directors overseeing the strategic direction.
Top Products and Market Share
Key Offerings
- NuQu00ae Assays: NuQu00ae is Volition's core technology platform, used to develop blood tests for cancer detection. Specific market share data is not publicly available. Competitors include companies developing liquid biopsy technologies, such as Exact Sciences (EXAS) and Guardant Health (GH).
Market Dynamics
Industry Overview
The cancer diagnostics industry is experiencing significant growth, driven by the increasing prevalence of cancer and the growing demand for early detection methods. Liquid biopsy, including blood-based tests, is a rapidly expanding segment.
Positioning
VolitionRx is positioned as a player in the early cancer detection market with a focus on nucleosomics technology. Their competitive advantage lies in their NuQu00ae platform, which offers the potential for accurate and cost-effective cancer screening.
Total Addressable Market (TAM)
The total addressable market (TAM) for cancer diagnostics is estimated to be in the tens of billions of dollars. VolitionRx is aiming to capture a portion of this market with its NuQu00ae platform.
Upturn SWOT Analysis
Strengths
- Proprietary NuQu00ae technology platform
- Potential for early cancer detection
- Simple, easy to use, cost effective blood tests
- Focused on a large and growing market
Weaknesses
- Limited commercial product portfolio
- Dependence on research and development
- Reliance on patents and intellectual property
- Historically, significant operating losses
Opportunities
- Expanding applications of NuQu00ae technology
- Partnerships and collaborations
- Increasing demand for early cancer detection
- Growing acceptance of liquid biopsy
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial risks
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- EXAS
- GH
- ILLU
Competitive Landscape
VolitionRx faces stiff competition from larger, well-established players in the cancer diagnostics market. Their NuQu00ae technology needs to demonstrate superior performance and cost-effectiveness to gain significant market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow and has relied heavily on financing
Future Projections: Future projections are dependent on the commercial success of NuQu00ae assays and partnerships.
Recent Initiatives: Recent initiatives have included progressing clinical trials and forming partnerships.
Summary
VolitionRx is a micro-cap company focused on cancer diagnostics using its NuQu00ae technology. The company is in a competitive market and is reliant on continued clinical trial success and partnerships. Financial performance has been a challenge historically, and the company requires external funding to operate. While the NuQu00ae technology holds promise, VolitionRx faces significant hurdles to achieve profitability and sustainable growth. Future market adoption is a key factor in whether the company can achieve its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Third-party Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Volitionrx Ltd
Exchange NYSE MKT | Headquaters Henderson, NV, United States | ||
IPO Launch date 2007-04-25 | Founder, CEO, President & Director Mr. Cameron Reynolds MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 82 | Website https://volition.com |
Full time employees 82 | Website https://volition.com | ||
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.